JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Home・Akciju saraksts・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Slēgts

SektorsVeselības aprūpe

36.88 -0.97

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

36.18

Max

37.08

Galvenie mērījumi
By Trading Economics
Ienākumi	11M 51M
Pārdošana	39M 239M
P/E Sektora vidējais	11.937 84.243
EPS	1.08
Peļņas marža	21.242
Darbinieki	268
EBITDA	14M 73M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+27.9% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	492M 2.2B
Iepriekšējā atvēršanas cena	37.85
Iepriekšējā slēgšanas cena	36.88

Ziņu noskaņojums

By Acuity

34%

66%

77 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

29.8 / N/A Atbalsts un pretestība

Harmony Biosciences Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. febr. 17:25 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

2026. g. 9. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

2026. g. 9. febr. 23:43 UTC

Tirgus saruna

Gold Falls on Possible Technical Correction -- Market Talk

2026. g. 9. febr. 23:14 UTC

Tirgus saruna

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

2026. g. 9. febr. 22:29 UTC

Tirgus saruna

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

2026. g. 9. febr. 22:19 UTC

Tirgus saruna

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

2026. g. 9. febr. 22:08 UTC

Tirgus saruna

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

2026. g. 9. febr. 22:01 UTC

Peļņas

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

2026. g. 9. febr. 21:59 UTC

Peļņas

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

2026. g. 9. febr. 21:59 UTC

Peļņas

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

2026. g. 9. febr. 21:58 UTC

Peļņas

Friedman Industries 3Q Sales $168M >FRD

2026. g. 9. febr. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 9. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. febr. 21:48 UTC

Peļņas

Friedman Industries 3Q EPS 43c >FRD

2026. g. 9. febr. 21:17 UTC

Peļņas

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

2026. g. 9. febr. 21:13 UTC

Tirgus saruna

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

2026. g. 9. febr. 21:04 UTC

Peļņas

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

2026. g. 9. febr. 20:30 UTC

Tirgus saruna

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

2026. g. 9. febr. 20:02 UTC

Tirgus saruna

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

2026. g. 9. febr. 19:42 UTC

Tirgus saruna

Japan's Yield Curve Expected to Flatten -- Market Talk

2026. g. 9. febr. 19:31 UTC

Tirgus saruna

Nike Seen Regaining Relevance With Consumers -- Market Talk

2026. g. 9. febr. 19:27 UTC

Tirgus saruna

Gold Climbs Back Over $5,000/oz -- Market Talk

2026. g. 9. febr. 19:05 UTC

Tirgus saruna

Nike Returns to List of Hottest Brands -- Market Talk

2026. g. 9. febr. 18:19 UTC

Tirgus saruna

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

2026. g. 9. febr. 17:41 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

2026. g. 9. febr. 17:31 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

2026. g. 9. febr. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 9. febr. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. febr. 17:17 UTC

Tirgus saruna

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

2026. g. 9. febr. 17:16 UTC

Peļņas

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Harmony Biosciences Holdings Inc Prognoze

Cenas mērķis

By TipRanks

27.9% augšup

Prognoze 12 mēnešiem

Vidējais 47.67 USD 27.9%

Augstākais 55 USD

Zemākais 42 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.8 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

77 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.